AC1903 MedChemExpress (MCE)

Product Name	1-Benzyl-N-(2-furylmethyl)-1H-benzimidazol-2-amine
Synonyms	AC1903 1-benzyl-N-(furan-2-ylmethyl)benzimidazol-2-amine 1-Benzyl-N-(2-furylmethyl)-1H-benzimidazol-2-amine 1-benzyl-N-(furan-2-ylmethyl)-1H-benzo[d]imidazol-2-amine 1H-Benzimidazol-2-amine, N-(2-furanylmethyl)-1-(phenylmethyl)-
CAS	831234-13-0
EINECS
Chemical Formula	C19H17N3O
Molecular Weight	303.36
inchi
Package	10 mM * 1 mL;5 mg;10 mg;25 mg;50 mg
Price	Email to quote
Descriptions	AC1903 AC1903 MedChemExpress (MCE) HY-122051 831234-13-0 99.80% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions AC1903 AC1903 MedChemExpress (MCE) HY-122051 831234-13-0 99.80% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model. TRPC5 is a Ca2+?permeable nonselective cation channel highly expressed in brain and kidney.AC1903 (0-100 μM) blocks riluzole-activated TRPC5 whole-cell current, but fails to block carbachol (CCh)–induced TRPC4 and OAG-induced TRPC6 currents, even at high micromolar concentrations in Patch-clamp electrophysiology experiments. The ICIC50 values of ML204 (HY-12949) (IC50=13.6 μM) and AC1903 (IC50=14.7 μM) are nearly equipotent in human embryonic kidney 293 (HEK-293) cells expressing TRPC5[1]. AC1903 (30 μM) inhibits angiotensin II-induced production of reactive oxygen species (ROS) in wild-type podocytes and podocytes expressing a mutant angiotensin II type 1 (AT1) receptor that cannot be inactivated and endocytosed[1].AC1903 (30 μM) blocks caAT1R-induced ROS generation. Increased podocyte cell death within 36 hours of caAT1R expression?is observed, but AC1903 ?protects podocyte cells from cell death[1]. AC1903 (intraperitoneal injection 50 mg/kg twice per day 7 days) significantly suppresses proteinuria as well as reduces pseudocyst formation and podocyte loss in an AT1?receptor transgenic rat model of kidney disease[1].AC1903 (intraperitoneal injection 50 mg/kg twice per day initiated on day 7 and treated for 1 week until day 14) initiatation on day 7 exhibits significant suppression of proteinuria with preserved podocyte numbers. Besides, AC1903 does not affect the mean arterial pressure (MAP) and exhibits no effect on body weight, blood urea nitrogen, or creatinine in Dahl S rats[1]. IC50: 14.7 μM (TRPC5 current IN HEK-293 cells)[1] In Vitro TRPC5 is a Ca2+?permeable nonselective cation channel highly expressed in brain and kidney.AC1903 (0-100 μM) blocks riluzole-activated TRPC5 whole-cell current, but fails to block carbachol (CCh)–induced TRPC4 and OAG-induced TRPC6 currents, even at high micromolar concentrations in Patch-clamp electrophysiology experiments. The ICIC50 values of ML204 (HY-12949) (IC50=13.6 μM) and AC1903 (IC50=14.7 μM) are nearly equipotent in human embryonic kidney 293 (HEK-293) cells expressing TRPC5[1]. AC1903 (30 μM) inhibits angiotensin II-induced production of reactive oxygen species (ROS) in wild-type podocytes and podocytes expressing a mutant angiotensin II type 1 (AT1) receptor that cannot be inactivated and endocytosed[1].AC1903 (30 μM) blocks caAT1R-induced ROS generation. Increased podocyte cell death within 36 hours of caAT1R expression?is observed, but AC1903 ?protects podocyte cells from cell death[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> AC1903 Related Antibodies Cell Viability Assay[1] Cell Line: Podocyte cells \| \| \| \| \| \| \| \| \| \| [1]. Yiming Zhou, et al. A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models. Science [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact